Skip to main content

Catalyst Calendar

Scope

Tue, Sep 29, 2026

1 updates
ARGX
8:00 AM

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data

Presentation / AbstractAANEM/MGFA scientific session presentations Tue, Sep 29, 2026argenx.com

Thu, Sep 17, 2026

1 updates

Tue, Sep 1, 2026

1 updates
ARGX
1:00 AM

argenx to Present at Upcoming Investor Conferences

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September: Wells Fargo 21st Annual Healthcare Conference.

argenx.com

Thu, Aug 27, 2026

1 updates
ARGX
8:50 AM

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte

argenx.com

Mon, Aug 17, 2026

1 updates

Thu, Aug 6, 2026

1 updates

Mon, Aug 3, 2026

1 updates

Mon, Jul 27, 2026

1 updates

Thu, Jul 23, 2026

1 updates

Thu, Jul 16, 2026

1 updates